Early Anterior Cruciate Ligament Reconstruction Reduces Long-Term Rates of Secondary Meniscus Surgery: A Systematic Review.

ArthroscopyJun 6, 2026 (epub)
Clinical ResearchOrthopedic Surgery

Litian Wang, Wenhao Lu, Gaoming Liu et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the effect of timing on anterior cruciate ligament reconstruction (ACLR) regarding secondary meniscus surgery rates in 933 patients. It found that early ACLR significantly reduces the long-term risk of secondary meniscus surgery compared to delayed ACLR, particularly in studies with follow-up durations greater than 5 years (P = .02).

Key findings

  • Early ACLR reduced the risk of secondary meniscus surgery in long-term follow-up (>5 years).
  • No significant difference in secondary meniscus surgery rates was found in follow-ups ≤5 years.
  • Longer follow-up duration correlated with an increasing trend in secondary meniscus surgery rates.

Why it matters

Understanding the timing of ACLR is crucial for optimizing patient outcomes, particularly in reducing the need for subsequent meniscus surgeries, which can impact long-term knee function and stability.

Source

PubMed · PMID 42249779

Published in Arthroscopy. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Orthopedic Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.